PAS
ELDN icon

Point72 Asia (Singapore)’s Eledon Pharmaceuticals ELDN Stock Holding History

Point72 Asia (Singapore)’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,866
Closed -$36.8K – 989
2025
Q1 		$36.8K Sell
10,866
-7,513
-41% -$30.9K 0.01% 617
2024
Q4 		$75.7K Buy
+18,379
New +$72.5K 0.02% 428

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Point72 Asia (Singapore)'s ELDN Position: Q2 2025 in Review

Point72 Asia (Singapore) sold out of Eledon Pharmaceuticals (ELDN) in Q2 2025, closing a stake of 10,866 shares — an estimated $36.8K sold.

Point72 Asia (Singapore) first reported a position in ELDN in Q4 2024 and held it in 2 quarters. The position peaked at $75.7K in Q4 2024. 85 funds tracked by Wall St. Rank hold ELDN as of Q2 2025.

  • Point72 Asia (Singapore) reported no remaining Eledon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 10,866 Eledon Pharmaceuticals shares in Q2 2025, an estimated $36.8K.
  • Point72 Asia (Singapore) first reported a position in Eledon Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Point72 Asia (Singapore)'s Eledon Pharmaceuticals position peaked at $75.7K in Q4 2024.
  • 85 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q2 2025, filed 14 Aug 2025.